Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.
about
Hyaluronidase expression and activity is regulated by pro-inflammatory cytokines in human airway epithelial cellsA functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysisSelected Aspects in the Pathogenesis of Autoimmune DiseasesAssociation of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population.Exhaled IL-8 in systemic lupus erythematosus with and without pulmonary fibrosis.Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines.Anti-TNF-alpha therapies in systemic lupus erythematosusWhat is Known About the Association of Antinuclear Antibodies Development During Treatment with TNF Blockers?Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.Current and novel therapeutics in the treatment of systemic lupus erythematosusCentral pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.Emerging roles for the interferon-inducible p200-family proteins in sex bias in systemic lupus erythematosus.Interferons in autoimmune and inflammatory diseases: regulation and roles.DNA-responsive inflammasomes and their regulators in autoimmunityUse of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis.Theory, targets and therapy in systemic lupus erythematosus.Anti-cytokine therapy in systemic lupus erythematosus.The respiratory system in connective tissue disorders.Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F.Development of biologicals for the therapy of lupus erythematosus.Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular diseaseFamilial aggregation of high tumor necrosis factor alpha levels in systemic lupus erythematosus.Malarial infection of female BWF1 lupus mice alters the redox state in kidney and liver tissues and confers protection against lupus nephritis.Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice.Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.The homeobox transcription factor VentX controls human macrophage terminal differentiation and proinflammatory activationTCF1 deficiency ameliorates autoimmune lymphoproliferative syndrome (ALPS)-like phenotypes of lpr/lpr mice.Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes.Ethnicity-stratified analysis of the association between IL-18 polymorphisms and systemic lupus erythematosus in a European population: a meta-analysis.Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease.Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation.Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure.Up-regulated renal expression of TNF-alpha signalling adapter proteins in lupus glomerulonephritis.Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation.Stabilized β-Catenin Ameliorates ALPS-Like Symptoms of B6/lpr Mice.Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus.Rheumatoid arthritis and periodontal disease: What are the similarities and differences?Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
P2860
Q24317310-AC095D6D-271C-4A34-A5FF-95FF95F3A355Q24680313-C63F4576-36BE-4A7F-BEAF-EDECC7496067Q26795580-C87B6016-1055-4CC0-A185-80C20949CBD7Q33392397-1CF5A415-7B1F-4BF9-9E7A-8BB72219F17CQ33624253-E6B734D6-FA14-4290-9D3B-FC7DCA07A653Q33676626-5596305E-6CC9-40EE-81A4-A4D5363CF549Q33960066-092E2858-AFF5-4569-A9C0-AB5A3FAE5256Q34455627-8BD9E899-0804-40B9-9055-00C4A6450DA4Q34556944-0CFD2581-C26E-436E-B174-787301B5B336Q34648851-BBF16C13-459E-47C5-8BF3-FE699EDCA518Q35059951-57FD89B1-1AB6-4112-A82E-C082EE8A78D7Q35603591-F710E9B3-E3C4-42FE-8F39-BE661283A065Q35603598-3782BD4A-50A6-415A-9B45-C8F14B9E1358Q35785671-808261BE-B773-48BD-87BB-F95F561FDAFBQ35888466-36BC2142-07E1-48BD-9123-095AA02EC2B3Q36088035-67F02725-C5D2-4AD8-ABE7-247EF2C91D4CQ36088040-DD7C122F-1217-4313-B33D-29B40512FAC8Q36117547-D30F6AB4-9155-4D08-B20C-AFB9D423EC96Q36577793-44391EE7-6572-437D-88C0-C73516CAAF94Q37012093-F062098D-C280-4EF8-B2DB-C2004CD8B300Q37078045-BF64E00B-BAD4-4CF5-9B13-722F730D1874Q37239812-3F839A28-4B6C-4AE0-9635-D430DEEF2579Q37351432-253F8C6F-5738-404B-B05A-E916BAE20978Q37673404-8AAB6D80-8754-49E7-9F8A-0E2E61C0249EQ38255986-B521276D-6DA5-40CA-BE8C-7507D9F3FD32Q38663003-1E53ACB2-6422-4F28-BC6D-0EC4188F2FA1Q39364591-B63F99D3-9077-45DE-B89E-8C55A96C7D56Q39609044-FD72C7A5-13AF-485A-BD9D-23EFE68A200EQ39665707-C734C8D5-B550-438A-9314-5680F5E49A56Q40886879-B78DF639-1D0E-46AE-B8D2-998415A54D3CQ42464517-9358F6E3-4FAD-41D4-8745-4C8EA9BB2295Q42876606-EB29A73C-04FF-4138-8A92-0382EFD449E8Q42972278-4E62B833-D0A3-4ED9-9339-48F0127EDFCEQ45093738-1AF40AEB-92C5-423B-AC51-13AEE37CBB72Q46158716-17B6FE0C-5B9B-4452-AB9E-38A9A66DCE4CQ47131684-E1E79F96-0A31-44D4-8C8A-62A0D893F432Q47136733-61A45742-36E4-496F-9911-69897AFAE3F6Q47422803-9DAD1761-2716-402A-B7FA-3849C800CDE2Q47653637-78B86309-7AC9-4610-B02D-75C8B0290906Q48718127-81A28A46-9116-4E68-B59E-4AD53CF9D0E7
P2860
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tumour necrosis factor and oth ...... for therapeutic intervention.
@ast
Tumour necrosis factor and oth ...... for therapeutic intervention.
@en
type
label
Tumour necrosis factor and oth ...... for therapeutic intervention.
@ast
Tumour necrosis factor and oth ...... for therapeutic intervention.
@en
prefLabel
Tumour necrosis factor and oth ...... for therapeutic intervention.
@ast
Tumour necrosis factor and oth ...... for therapeutic intervention.
@en
P2860
P1433
P1476
Tumour necrosis factor and oth ...... for therapeutic intervention.
@en
P2093
P2860
P304
P356
10.1191/0961203303LU1024OA
P577
2004-01-01T00:00:00Z